Literature DB >> 29845425

A Novel PET Probe "[18F]DiFA" Accumulates in Hypoxic Region via Glutathione Conjugation Following Reductive Metabolism.

Yoichi Shimizu1,2,3, Songji Zhao4, Hironobu Yasui5,4, Ken-Ichi Nishijima5, Hiroki Matsumoto6, Tohru Shiga4, Nagara Tamaki4, Mikako Ogawa7, Yuji Kuge5,4.   

Abstract

PURPOSE: Hypoxia in tumor has close relationship with angiogenesis and tumor progression. Previously, we developed 2,2-dihydroxymethyl-3-[18F]fluoropropyl-2-nitroimidazole ([18F]DiFA) as a novel positron emission tomography (PET) probe for diagnosis of hypoxia. In this study, we elucidated whether the accumulation of [18F]DiFA in cells is dependent on the hypoxic state and revealed how [18F]DiFA accumulates in hypoxic cells in combination with imaging mass spectrometry (IMS). PROCEDURES: FaDu human head and neck cancer cells were treated with [18F]DiFA and then incubated under normoxia (21% O2) or hypoxia (1% O2) for 2 h. The cells were extracted using methanol, and the radioactivities of the precipitates (macromolecule fraction) and supernatants (low-molecular-weight fraction) were measured. FaDu-bearing mice were injected intravenously with [18F]DiFA and with pimonidazole 1 h later. The tumors were excised 2 h after the injection of [18F]DiFA. Autoradiography, IMS, and immunohistochemical (IHC) staining for pimonidazole were performed with serial tumor sections.
RESULTS: In the in vitro study, the radioactivity of FaDu cells was significantly higher under hypoxia than that under normoxia (0.53 ± 0.02 vs. 0.27 ± 0.02 %dose/mg protein, p < 0.05). The radioactivity of the low-molecular-weight fraction was 66.3 ± 0.6% in the hypoxic cell. In the in vivo study, [18F]DiFA accumulated in the tumor tissues existed mainly as low-molecular-weight compounds (90.4 ± 0.9%). In addition, the glutathione conjugate of reductive DiFA metabolite (amino-DiFA-GS) existed in tumor tissues revealed by the IMS study, and the distribution pattern of amino-DiFA-GS was very similar to that of the radioactivity and the positive staining area of pimonidazole.
CONCLUSIONS: Our results suggest that [18F]DiFA undergoes the glutathione conjugation reaction following reductive metabolism in hypoxic cells, which leads hypoxia-specific PET imaging with [18F]DiFA.

Entities:  

Keywords:  DiFA; Glutathione; Hypoxia; Imaging mass spectrometry; Molecular imaging

Mesh:

Substances:

Year:  2019        PMID: 29845425     DOI: 10.1007/s11307-018-1214-y

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  22 in total

1.  Characterization and performance of MALDI on a triple quadrupole mass spectrometer for analysis and quantification of small molecules.

Authors:  Jason Gobey; Mark Cole; John Janiszewski; Thomas Covey; Tung Chau; Peter Kovarik; Jay Corr
Journal:  Anal Chem       Date:  2005-09-01       Impact factor: 6.986

2.  Role of glutathione in cisplatin resistance in osteosarcoma cell lines.

Authors:  S Komiya; M C Gebhardt; D C Mangham; A Inoue
Journal:  J Orthop Res       Date:  1998-01       Impact factor: 3.494

Review 3.  PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence.

Authors:  Egesta Lopci; Ilaria Grassi; Arturo Chiti; Cristina Nanni; Gianfranco Cicoria; Luca Toschi; Cristina Fonti; Filippo Lodi; Sandro Mattioli; Stefano Fanti
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-06-07

4.  Molecular imaging of biological samples: localization of peptides and proteins using MALDI-TOF MS.

Authors:  R M Caprioli; T B Farmer; J Gile
Journal:  Anal Chem       Date:  1997-12-01       Impact factor: 6.986

5.  High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer.

Authors:  Shozo Okamoto; Tohru Shiga; Koichi Yasuda; Yoichi M Ito; Keiichi Magota; Katsuhiko Kasai; Yuji Kuge; Hiroki Shirato; Nagara Tamaki
Journal:  J Nucl Med       Date:  2013-01-15       Impact factor: 10.057

Review 6.  Imaging in the era of molecular oncology.

Authors:  Ralph Weissleder; Mikael J Pittet
Journal:  Nature       Date:  2008-04-03       Impact factor: 49.962

7.  Reduction of fluoromisonidazole, a new imaging agent for hypoxia.

Authors:  J L Prekeges; J S Rasey; Z Grunbaum; K H Krohn
Journal:  Biochem Pharmacol       Date:  1991-11-27       Impact factor: 5.858

8.  Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors.

Authors:  J A Raleigh; S C Chou; G E Arteel; M R Horsman
Journal:  Radiat Res       Date:  1999-05       Impact factor: 2.841

9.  Matrix-suppressed laser desorption/ionisation mass spectrometry and its suitability for metabolome analyses.

Authors:  Seetharaman Vaidyanathan; Simon Gaskell; Royston Goodacre
Journal:  Rapid Commun Mass Spectrom       Date:  2006       Impact factor: 2.419

10.  FMISO accumulation in tumor is dependent on glutathione conjugation capacity in addition to hypoxic state.

Authors:  Yukiko Masaki; Yoichi Shimizu; Takeshi Yoshioka; Ken-Ichi Nishijima; Songji Zhao; Kenichi Higashino; Yoshito Numata; Nagara Tamaki; Yuji Kuge
Journal:  Ann Nucl Med       Date:  2017-07-10       Impact factor: 2.668

View more
  2 in total

1.  Increased [18F]FMISO accumulation under hypoxia by multidrug-resistant protein 1 inhibitors.

Authors:  Yoichi Shimizu; Yukihiro Nakai; Hiroyuki Watanabe; Shimpei Iikuni; Masahiro Ono; Hideo Saji; Yuji Kuge; Tsuneo Saga; Yuji Nakamoto
Journal:  EJNMMI Res       Date:  2021-01-25       Impact factor: 3.138

Review 2.  Enzymatic synthesis of fluorinated compounds.

Authors:  Xinkuan Cheng; Long Ma
Journal:  Appl Microbiol Biotechnol       Date:  2021-10-09       Impact factor: 4.813

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.